newsfilter
← Latest News
GlobeNewswire·

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Vera Therapeutics granted inducement awards on November 2, 2026, to three new employees under its 2024 Inducement Plan.
  • The awards consist of non-qualified stock options for 14,900 shares & restricted stock units (RSUs) for 7,450 shares of Class A common stock.
  • Stock options have an exercise price of $30.25 per share, based on the closing trading price on the grant date.
  • Stock options vest over four years, with 25% vesting on the first anniversary & the remainder vesting monthly over the subsequent 36 months.
  • RSUs vest over four years, with 25% vesting annually on November 20 starting from the grant date.
  • All awards are subject to continued employment & the terms of the Inducement Plan & applicable award agreements.
  • Vera Therapeutics is a commercial-stage biotechnology company based in Brisbane, California, focused on autoimmune kidney disease & its flagship product TRUTAKNA.
Company
Vera Therapeutics
Keywords
Nasdaq:VERA, Vera Therapeutics, vera therapeutics